The proposal is a phase II clinical study designed to assess the feasibility of durvalumab
(MEDI4736) in HIV-1-infected individuals with solid tumors. Additionally, to obtain data that
lets understand the possible benefit of this treatment in cancer patients and HIV infection,
exploring if activity of durvalumab (MEDI4736) could be higher in cancer that has been
produced at least in part due to the chronic immunosupression. Simultaneously, it will allow
us to investigate the effect of disrupting this immunoregulatory pathway might have in
reversing cancer pathways and HIV-specific T-cell function during persistent chronic HIV
infection in humans.